EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

Ryan J Duchatel, Evangeline R Jackson, Sarah G Parackal, Dylan Kiltschewskij, Izac J Findlay, Abdul Mannan, Dilana E Staudt, Bryce C Thomas, Zacary P Germon, Sandra Laternser, Padraic S Kearney, M Fairuz B Jamaluddin und 43 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci170329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Ryan J Duchatel und 54 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Cal…. Hauptthemen laut MEDLINE: Diffuse Intrinsic Pontine Glioma, Brain Stem Neoplasms, Glioma, Metformin. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC Investigator Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse midline glioma (DMG), including tumors diagnosed in the brainstem (diffuse intrinsic pontine glioma; DIPG), are uniformly fatal brain tumors that lack effective treatment. Analysis of CRISPR/Cas9 loss-of-function gene deletion screens identified PIK3CA and MTOR as targetable molecular dependencies across patient derived models of DIPG, highlighting the therapeutic potential of the blood-brain barrier–penetrant PI3K/Akt/mTOR inhibitor, paxalisib. At the human-equivalent maximum tolerated dose, mice treated with paxalisib experienced systemic glucose feedback and increased insulin levels commensurate with patients using PI3K inhibitors. To exploit genetic dependence and overcome resistance while maintaining compliance and therapeutic benefit, we combined paxalisib with the antihyperglycemic drug metformin. Metformin restored glucose homeostasis and decreased phosphorylation of the insulin receptor in vivo, a common mechanism of PI3K-inhibitor resistance, extending survival of orthotopic models. DIPG models treated with paxalisib increased calcium-activated PKC signaling. The brain penetrant PKC inhibitor enzastaurin, in combination with paxalisib, synergistically extended the survival of multiple orthotopic patient-derived and immunocompetent syngeneic allograft models; benefits potentiated in combination with metformin and standard-of-care radiotherapy. Therapeutic adaptation was assessed using spatial transcriptomics and ATAC-Seq, identifying changes in myelination and tumor immune microenvironment crosstalk. Collectively, this study has identified what we believe to be a clinically relevant DIPG therapeutic combinational strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diffuse Intrinsic Pontine GliomaBrain Stem NeoplasmsGliomaMetforminHumansMiceAnimalsPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesProtein Kinase InhibitorsPhosphoinositide-3 Kinase InhibitorsGlucoseTumor Microenvironment

Stichwörter der Autor:innen

Brain cancerDrug therapyOncogenesOncologyTherapeutics

Substanzen

Phosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesProtein Kinase InhibitorsPhosphoinositide-3 Kinase InhibitorsGlucoseMetformin

Autor:innen und Institutionen

  • Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
  • Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
  • Paediatric Stream, Mark Hughes Foundation Centre for Brain Cancer Research, College of Health, Medicine, and Wellbeing, Callaghan, New South Wales, Australia.
  • Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
  • Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia.
  • School of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.

Förderung

  • NHMRC Investigator Grant

Zitieren

APA

Duchatel, R. J., Jackson, E. R., Parackal, S. G., Kiltschewskij, D., Findlay, I. J., Mannan, A., Staudt, D. E., Thomas, B. C., Germon, Z. P., Laternser, S., Kearney, P. S., Jamaluddin, M. F. B., Douglas, A. M., Beitaki, T., McEwen, H. P., Persson, M. L., Hocke, E. A., Jain, V., Aksu, M., …, & Dun, M. D. (2024). PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma. Journal of Clinical Investigation. https://doi.org/10.1172/jci170329

Vancouver

Duchatel RJ, Jackson ER, Parackal SG, Kiltschewskij D, Findlay IJ, Mannan A, et al. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma. Journal of Clinical Investigation. 2024. doi:10.1172/jci170329

BibTeX
@article{Duchatel2024,
  author = {Duchatel, Ryan J and Jackson, Evangeline R and Parackal, Sarah G and Kiltschewskij, Dylan and Findlay, Izac J and Mannan, Abdul and Staudt, Dilana E and Thomas, Bryce C and Germon, Zacary P and Laternser, Sandra and Kearney, Padraic S and Jamaluddin, M Fairuz B and Douglas, Alicia M and Beitaki, Tyrone and McEwen, Holly P and Persson, Mika L and Hocke, Emily A and Jain, Vaibhav and Aksu, Michael and Manning, Elizabeth E and Murray, Heather C and Verrills, Nicole M and Sun, Claire Xin and Daniel, Paul and Vilain, Ricardo E and Skerrett-Byrne, David A and Nixon, Brett and Hua, Susan and de Bock, Charles E and Colino-Sanguino, Yolanda and Valdes-Mora, Fatima and Tsoli, Maria and Ziegler, David S and Cairns, Murray J and Raabe, Eric H and Vitanza, Nicholas A and Hulleman, Esther and Phoenix, Timothy N and Koschmann, Carl and Alvaro, Frank and Dayas, Christopher V and Tinkle, Christopher L and Wheeler, Helen and Whittle, James R and Eisenstat, David D and Firestein, Ron and Mueller, Sabine and Valvi, Santosh and Hansford, Jordan R and Ashley, David M and Gregory, Simon G and Kilburn, Lindsay B and Nazarian, Javad and Cain, Jason E and Dun, Matthew D},
  title = {PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci170329}
}
Kostenlos starten →